Results 21 to 30 of about 92,873 (239)

Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Frontiers in Cell and Developmental Biology, 2022
Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation.
Mohummad Aminur Rahman, Mohummad Aminur Rahman, Agnete S. T. Engelsen, Agnete S. T. Engelsen, Shahin Sarowar, Christian Bindesbøll, Even Birkeland, Dorota Goplen, Maria L. Lotsberg, Maria L. Lotsberg, Stian Knappskog, Stian Knappskog, Anne Simonsen, Anne Simonsen, Anne Simonsen, Martha Chekenya   +15 more
doaj   +1 more source

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma [PDF]

, 2018
Background: The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM).
Chen, Yi, Colapietro, Alessandro, Cristiano, Loredana, Delle Monache, Simona, Festuccia, Claudio, Gravina, Giovanni Luca, Mancini, Andrea, Marampon, Francesco, Mehrling, Thomas, Pompili, Simona, Tombolini, Vincenzo, Vetuschi, Antonella, Vitale, Flora   +12 more
core   +2 more sources

Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model

Neoplasia: An International Journal for Oncology Research, 2008
Purpose: The aims of the present work were to investigate the in vitro and in vivo antiangiogenic effects of chronic temozolomide treatment on various glioma models and to demonstrate whether bevacizumab (Avastin) increased the therapeutic benefits ...
Véronique Mathieu, Nancy De Nève, Marie Le Mercier, Janique Dewelle, Jean-François Gaussin, Mischael Dehoux, Robert Kiss, Florence Lefranc   +7 more
doaj   +1 more source

The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. [PDF]

, 2017
The aim of the present study was to determine the usefulness of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of a doxorubicin-resistant metastatic Ewing's sarcoma, with a unique combination of a FUS-ERG fusion and CDKN2A deletion, to ...
Bouvet, Michael, Chishima, Takashi, Dry, Sarah M, Eckardt, Mark A, Eilber, Fritz C, Elliott, Irmina A, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Yunfeng, Matsuyama, Ryusei, Miyake, Kentaro, Miyake, Masuyo, Momiyama, Masashi, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Singh, Arun S   +20 more
core   +1 more source

Regulation of CD4+NKG2D+ Th1 cells in patients with metastatic melanoma treated with sorafenib : role of IL-15Rα and NKG2D triggering [PDF]

, 2014
Beyond cancer-cell intrinsic factors, the immune status of the host has a prognostic impact on patients with cancer and influences the effects of conventional chemotherapies.
Auperin, Anne, Ayyoub, Maha, Caignard, Anne, Caillat-Zucman, Sophie, Chaba, Kariman, Chaput, Nathalie, Dessen, Philippe, Eggermont, Alexander, Flament, Caroline, Jacquelot, Nicolas, Jacques, Yannick, Mateus, Christine, Messaoudene, Meriem, Mortier, Erwan, Poirier-Colame, Vichnou, Porta, Camillo, Robert, Caroline, Romero, Ana I., Rusakiewicz, Sylvie, Valmor, Danila, Vielh, Philippe, Zitvogel, Laurence   +21 more
core   +2 more sources

GBM radiosensitizers: dead in the water…or just the beginning? [PDF]

, 2017
The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control.
Bindra, Ranjit S., Chalmers, Anthony J., Dewhirst, Mark, Evans, Sydney   +3 more
core   +1 more source

An Unusual Case of Aplastic Anemia Caused by Temozolomide

Case Reports in Medicine, 2010
Radiotherapy and concomitant/adjuvant therapy with temozolomide are a common treatment regimen for children and adults with high-grade glioma. Although temozolomide is generally safe, it can rarely cause life-threatening complications.
Gazi Comez, Alper Sevinc, Ozlem Nuray Sever, Taner Babacan, Ibrahim Sarı, Celalettin Camci   +5 more
doaj   +1 more source

Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. [PDF]

, 2015
BackgroundTemozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with glioblastoma. However, therapeutic benefits of TMZ can be compromised by the expression of O6-methylguanine methyltransferase (MGMT) in tumor tissue.
Bui, Yvonne, Cloughesy, Timothy F, Hong, Irene, Lai, Albert, Liau, Linda M, McBride, William H, Menjivar, Jimmy C, Nelson, Stanley F, Stream, Alexandra, Tso, Cho-Lea, Tso, Jonathan L, Yamada, Kazunari, Yang, Shuai, Yong, William H, Zhang, Yibei   +14 more
core   +2 more sources

Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide. [PDF]

, 2018
Resistance to chemotherapy substantially hinders successful glioblastoma (GBM) treatment, contributing to an almost 100% mortality rate. Resistance to the frontline chemotherapy, temozolomide (TMZ), arises from numerous signaling pathways that are ...
Day, Emily S, Gleghorn, Jason P, Ioele, Stephen A, Melamed, Jilian R, Morgan, Joshua T, Sims-Mourtada, Jennifer   +5 more
core   +1 more source

Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report

Journal of Medical Case Reports, 2010
Introduction We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be ...
Shaikh Asim, Masood Nehal
doaj   +1 more source